Phase II Trial Opens: AI Chatbot-Enabled Nurse-Led Program vs Standard Care in Early CKM Syndrome — What Clinicians Need to Know

References

1. 1.Taipei Medical University. (2024). AI Chatbot-Enabled ePRO Symptom Monitoring and Self-Management for Early Cardiovascular-Kidney-Metabolic Syndrome. ClinicalTrials.gov. NCT07577284. https://clinicaltrials.gov/study/NCT07577284
2. 2.Chen, T. K., Knicely, D. H., & Grams, M. E. (2019). Chronic kidney disease diagnosis and management: A review. JAMA, 322(13), 1294-1304. https://doi.org/10.1001/jama.2019.4988
3. 3.Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., ... & American Heart Association. (2023). Cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association. Circulation, 148(20), 1606-1635. https://doi.org/10.1161/CIR.0000000000001184
4. 4.Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022). Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney International, 102(2), 248-260. https://doi.org/10.1016/j.kint.2022.05.012
5. 5.Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O'Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. R. (2016). Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PLoS One, 11(7), e0158765. https://doi.org/10.1371/journal.pone.0158765
6. 6.Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318(2), 197-198. https://doi.org/10.1001/jama.2017.7156